Recommendation 125: We recommend starting or continuing the use of ACEi/ARBs, and beta-blockers in patients with heart failure and on chronic dialysis (Strong Recommendation, Moderate Quality Evidence).

Values and preferences: The use of MRAs in hemodialysis patients with heart failure has been shown to reduce mortality.